A Phase 3, Open Label Trial Evaluating the Safety,Tolerability and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Children Aged 15 Months to 17 Years in the United States.
Phase of Trial: Phase III
Latest Information Update: 30 Jul 2013
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors Pfizer; Wyeth
- 09 Aug 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 20 Oct 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 20 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.